Hematology/Oncology at UPenn

Barbara A. Konkle, MD Medline search
Associate Professor of Medicine
Director, Penn Comprehensive Hemophilia and Thrombosis Program

Hematology-Oncology
Presbyterian Medical Center
Medical Arts Building 103
39^th and Market St.
Philadelphia, PA 19104

Phone: (215) 662-9248
FAX: (215) 243-4621

Board Certified
Internal Medicine
Hematology
Medical Oncology

Residency
Internal Medicine
Rush-Presbyterian-St. Lukes, Chicago

Fellowship
Hematology-Oncology
University of Michigan

The Penn Comprehensive Hemophilia and Thrombosis Program, which Dr. Konkle directs, provides comprehensive care for patients with inherited and acquired disorders of hemostasis. There is a special emphasis on inherited bleeding disorders, including hemophilia and von Willebrand disease, and in inherited disorders predisposing individuals to thrombosis. Patients receive a comprehensive approach through the involvement of trained nursing, social work, physical therapy, genetic counseling personnel, as well as an ongoing relationship with other specialist physicians and home care agencies with expertise in caring for patients with disorders of hemostasis.

Research activities including the Universal Data Collection system, funded by the Centers for Disease Control, to survey for blood borne pathogens and follow joint mobility in patients with inherited bleeding disorders; the Multicenter Hemophilia Cohort Study, funded by the NCI, an epidemiologic study of HIV and hepatitis infection in patients with inherited bleeding disorders; studies of new drugs for the treatment of bleeding and thrombotic disorders, including study of patients with inhibitors to factor VIII and studies of new anticoagulants; study of treatment of menorrhagia in women with von Willebrand disease or who are symptomatic carriers of hemophilia A; studies of pathophysiology and treatment of heparin-induced thrombocytopenia; and, a study correlating various laboratory parameters of von Willebrand function with bleeding symptoms in multigenerational families with von Willebrand disease.

Representative Publications

Palermo C and Konkle BA: Laboratory Evaluation of the Hypercoagulable State. Treatment and Prevention of Thrombosis: Issues for the Primary Care Physician. Merli G, Konkle BA, Spandorfer J, eds. Chapman and Hall, New York, NY (In press), 2001.

Stein S and Konkle BA: Thrombotic Risk of Oral Contraceptives, Post-Menopausal Hormone Replacement and SERMS. Consultative Hemostases and Thrombosis. Kitchens C, Alving, BM, Kessler, CM, eds. Saunders, New York, NY (In press), 2001

Salkowitz J, Goedert J, Konkle B, Aledort L, Eyster E, Koup R, White GC, Lederman M. 2001. Characterization of high risk HIV-1 seronegative hemophiliacs. Clin Immunol.(In press).

Crescenzo R and Konkle BA: Treatment Choices in Hemophilia A and B. Blood Products and Pharmacologic Agents in the Treatment of Congenital and Acquired Bleeding Disorders. Alving B, ed. American Association of Blood Banks Press. Bethesda, MD. pp. 309-339, 2000.

Bauer TL, Arepally G, Konkle BA, Mestichelli B, Shapiro SS, Cines DB, Poncz M, McNulty S, Amiral J, Hauck WW, Edie RN, Manion JD. 1997. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 95:1242-1246.

Goedert JJ, Erdman DD, Konkle BA, Torok TJ, Lederman MM, Kleinert D, Mandalaki T, Kessler CM, Anderson LJ, Luban NL. 1997. Parvovirus B 1 9 quiescence during the course of human immunodeficiency virus infection in persons with hemophilia. Am. J Hematol 56:248-25 1.

Ludlow LB, Schick BP, Budarf ML, Driscoll DA, Zachai EH, Cohen A, Konkle BA. 1996. Identification of a mutation in a GATA binding site of the platelet glycoprotein lbb promoter resulting in the Bernard Soulier Syndrome. J Biol Chem 271:22076-22080.

Konkle BA: The laboratory evaluation of von Willebrand disease (Editorial) Clin. Chem 41:489, 1995.